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Abstract
Cancer chemotherapy inhibits tumor growth, in part, by triggering apoptosis, and anti-apoptotic proteins reduce the effectiveness of
chemotherapy. Clusterin, a chaperone-like protein that binds to apoptotic and DNA repair proteins, is induced by chemotherapy and promotes
tumor cell survival. Histone deacetylase inhibitors (HDIs) such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) are
pharmacological agents that induce differentiation and apoptosis in cancer cells by altering chromatin structure, and we have found that
combinations of chemotherapeutic drugs such as doxorubicin and HDIs efficiently induce apoptosis, even though they paradoxically induce high
levels of clusterin. The hyper-expressed form of clusterin localizes to mitochondria, inhibits cytochrome c release, and is inhibited by the
proteasome. When HDIs are used as single agents, clusterin suppresses cytochrome c release and apoptosis. However, doxorubicin/HDI-induced
apoptosis is not inhibited by clusterin, and clusterin-resistant apoptosis corresponds with markers of the extrinsic/receptor-mediated apoptotic
pathway. Thus, chemotherapy–HDI combinations are capable of overcoming an innate anti-apoptotic pathway of tumor cells, suggesting that
chemotherapy–HDI combinations have potential for treating advanced stage breast cancer.
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Cancer cells are characterized by increased DNA replication,
and many types of cancer chemotherapy target dividing cells by
damaging DNA or inhibiting DNA replication. Doxorubicin and
etoposide inhibit topoisomerase II, while camptothecins inhibit
topoisomerase I [1], and the resulting DNA damage triggers
apoptosis. Cancer cells develop resistance to DNA damaging
agents, in part, by circumventing apoptotic pathways that are
present in non-malignant cells [2]. Histone deacetylase inhibi-
tors (HDIs) are small molecules that preferentially induce
apoptosis in cancer cells [3] and also induce differentiation [3,4].
The binding site for HDIs resembles a pocket which contains a
Zinc atom [3], and a broad variety of compounds have HDI
activity. Several of these are in clinical trials for cancer [5]. HDIs
have also been used in combination with various anti-neoplastic
drugs, generally increasing their tumoricidal activity [6–10].⁎ Corresponding author. Tel.: +1 859 323 3832; fax: +1 859 257 9608.
E-mail address: rolf.craven@uky.edu (R.J. Craven).
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doi:10.1016/j.bbadis.2007.06.004Histone deacetylase inhibitors function, in part, by altering the
expression of numerous genes that regulate differentiation
[11,12], apoptosis [13], and components of the proteasome [14].
When exposed to apoptotic stresses, a number of cell types
induce clusterin, a pro- or anti-apoptotic protein with chaperone
activity [15]. Clusterin, which is also called apolipoprotein J and
testosterone repressed prostate message 2 [16], among others, is
strongly induced by chemotherapy [17–21], and clusterin up-
regulates chemotherapy resistance in tumor cell lines [19,22,23].
Clusterin is overexpressed in some tumors [1,24–28], where it
presumably suppresses apoptosis during cellular transformation
and metastasis. Clusterin expression decreases in other tumors
[18,28], where it may play a pro-apoptotic role. In some cell
types, clusterin is synthesized as a pro-form that is glycosylated,
cleaved, and secreted as a heterodimer [16]. Clusterin is also
expressed as an intracellular variant [29–31] that can arise
through alternate splicing of exons 1 and 3 [32] or as a non-
glycosylated full-length protein that is not a splice variant [33].
A number of additional modifications can also alter the
electrophoretic mobility of clusterin.
Fig. 1. Apoptosis is induced by doxorubicin combined with the histone
deacetylase inhibitor sodium butyrate (HDI). (A) Western blot for polyADP
ribose polymerase (PARP), a marker of apoptosis, or tubulin as a control for
protein loading (lower panel). MDA-MB-231 cells were either untreated (lane 1),
or treated with 5 mM HDI (sodium butyrate, lane 2), fixed concentrations of HDI
with 0.04, 0.2, or 1 μM doxorubicin (lanes 3–5), or the same concentrations of
doxorubicin alone (lanes 6–8). The p85 form of PARP is a marker for apoptosis.
(B–E) Flow cytometry of MDA-MB-231 cells showing the induction of apoptosis
by doxorubicin plus HDIs. The sub-G1 DNA is the left-most peak in panel E.
Cells were untreated panel B or treated with 1 μM doxorubicin panel C, 5 mM
sodium butyrate (panel D), or the same doses of doxorubicin and sodium butyrate
in combination panel E. Samples were analyzed 48 h after initiating treatment.
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endoplasmic reticulum or mitochondria [34,35], where it binds
to Bax, a pro-apoptotic member of the Bcl-2 protein family, and
suppresses apoptosis [34]. Following cellular damage, Bax and
Bak form a membrane pore through which cytochrome c and
other mitochondrial proteins are released into the cytoplasm
[36]. Cytochrome c then nucleates the formation of the apopto-
some, which activates caspase 3 [37]. Clusterin binds directly to
Bax and inhibits its oligomerization, but does not alter its
conformation or localization [34]. Other clusterin splice variants
localize to the nucleus, where they bind to Ku70 [30], a DNA
repair protein [38], and promote apoptosis [30].
We found previously that clusterin was induced by doxo-
rubicin in the p53-negative breast cancer cell line MDA-MB-
231, but not in p53-positive MCF-7 cells [17]. Furthermore,
inhibiting clusterin induction by RNAi sensitized the cells to
doxorubicin [17]. Similar results were detected in osteosarcoma
cells [19]. In the present study, we demonstrate that clusterin is
regulated transcriptionally and post-transcriptionally by histone
deacetylases. We also show that clusterin inhibits HDI-induced
apoptosis by suppressing the intrinsic/mitochondrial apoptotic
pathway, but that the ability of clusterin to suppress apoptosis is
overcome by combinations of chemotherapy and HDIs. Our
findings suggest that cellular chemoresistance pathways can be
circumvented by novel chemotherapy combinations that activate
multiple apoptotic pathways.
2. Materials and methods
2.1. Cell growth and treatments
MDA-MB-231 and MDA-MB-435S [39] cells were maintained Dulbecco's
modified Eagle medium containing 10% serum supreme supplemented with
penicillin and streptomycin. Doxorubicin (Sigma, St. Louis, MO), camptothecin
(Sigma), etoposide (Sigma), sodium butyrate (Alfa Aesar, Ward Hill, MA), and
SAHA (Biomol, PlymouthMeeting, PA) were used at doses indicated in the text.
For RNAi transfections, cells (500,000/100 mm dish) were transfected with
220 pmol of RNA oligonucleotide duplexes (clusterin third exon, Ambion ID
#146049) diluted in 1 ml of Opti-MEMmedium and Oligofectamine (both from
Invitrogen, Carlsbad, CA) as described [17]. After an overnight incubation, cells
were split in normalmedium to a density of 500,000cells/100mmdish and treated
with the indicated drugs. Cells were then harvested 24–48 h after drug addition.
2.2. Expression analysis
For western blots, cells were lysed in NP-40 buffer (1% NP-40, 20 mM Tris,
150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, pH 7.4, and 10 μg/ml of the
protease inhibitors aprotinin and leupeptin), separated by SDS-PAGE, transferred
to Immobilon P membranes (Millipore, Billerica, MA), and probed as described
[40]. The antibodies to clusterin (C-18, #sc-6419), PARP (F-2), pro-caspase 3 (H-
227), cytochrome c (A-8), Akt (B-5), Ku70 (A-9), IκBα (H-4) and Bax (2D2)
were from Santa Cruz Biotechnologies (Santa Cruz, CA), and were used at a
dilution of 1:1000. The clusterin C-18 immunogenic peptide for the C-18 antibody
was from Santa Cruz. Antibodies to Fas ligand, RIP, FADD and pro-caspase 8
were from Transduction Labs/BD Biosciences (San Jose, CA). Other antibodies
were to tubulin (Labvision/Neomarkers, Inc., Fremont, CA, used at a dilution of
1:2000) and cytochrome c oxidase IV, sub-unit II (COX II, 12C4, Invitrogen).
For RT-PCR, MDA-MB-231 cells were treated with various drugs, and RNA
was purified, reverse transcribed with random hexamers, and amplified using Taq
polymerase (GenScript, Piscataway, NJ) in an Eppendorf Master Cycler
(Eppendorf, Westbury, NY) for 26–36 cycles of 94 °C for 1 min, 55 °C for 1
min, and 72 °C for 1 min. PCR reactions contained primers to clusterin and actin,which served as an internal control for cDNA loading. The primer sequences were
hCLU-5′ (ACAGGGTGCCGCTGACC), as described byLeskov [32], andCLU+
260R (TGGTCTCATTTAGGGCATCC) for clusterin. The actin primers have
been described previously [41]. PCR products were visualized by electrophoresis
in 2% agarose 1000 (Invitrogen).
2.3. FACS analysis and caspase 8 assays
FACS analysis was performed by fixing cells after 48 h treatment in ethanol
and resuspending them in phosphate-buffered saline containing 20 μg/ml
propidium iodide and 20 μg/ml DNase-free RNase, as described previously [17].
For caspase 8 activity assays, approximately 107 cells were lysed in 100 μl of
lysis buffer (50 mMHEPES, pH 7.4, 0.1%CHAPS, 1mMdithiothreitol, 0.1 mM
EDTA, 0.1% NP-40). Caspase activity was measured in triplicate in a reaction
containing 20 μl of lysate, 70 μl of reaction buffer (50 mMHEPES, pH 7.4, 0.1%
CHAPS, 100 mMNaCl, 10 mM dithiothreitol, and 1 mM EDTA), and 10 μl of 1
mg/ml Ac-IETD-pNA (N-acetyl-Ile-Glu-Thr-Asp p-nitroanilide, Biomol, Inc.).
The reaction was incubated at 37°C, and the absorbance at 405 nmwas measured
after 1, 2, and 3 h. Protein content was measured by Bradford assay, and the
activity was calculated as pmoles pNA cleaved/μg protein/minute.
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For mitochondrial fractionation, MDA-MB-231 cells were treated,
harvested, and lysed in digitonin lysis buffer (75 mM NaCl, 1 mM NaH2PO4,
8 mM Na2HPO4, 250 mM sucrose, 190 μg/ml digitonin; 250 μl /100 mm dish)
on ice for 5 min, and then centrifuged at 13,000×g for 5 min at 4°C, as described
[42]. The pellets were resuspended in radioimmunoprecipitation (RIPA) buffer
(1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
150 mM sodium chloride, and 1 mM NaH2PO4, 8 mM Na2HPO4) on ice for
30 min and then centrifuged at 13,000×g for 10 min. The supernatant was then
sheared by 5–10 passages through a 26-gauge needle.
The procedure for immunofluorescence has been described recently. Briefly,
cells were fixed in 3.7% formaldehyde, permeabilized in 0.1% Triton X-100,
pre-hybridized with 10% fetal bovine serum, incubated with the anti-clusterin C-
18 antibody (Santa Cruz) at a dilution of 1:100, and detected with a Texas Red-
labeled anti-goat secondary antibody. COX-II was visualized using the 12C4
monoclonal antibody at a dilution of 1:100 and a FITC-labeled anti-mouse
secondary. Cells were detected using a Leica TCS confocal microscope.3. Results
3.1. Histone deacetylase inhibitors elevate clusterin stability in
doxorubicin-treated cells
MDA-MB-231 human breast cancer cells are largely resistant
to chemotherapy-induced apoptosis. However, co-administra-
tion of 0–1 μM of the topoisomerase II inhibitor doxorubicin
(adriamycin) with the histone deacetylase inhibitor (HDI)Fig. 2. Clusterin levels are induced by doxorubicin and histone deacetylase inhibitors
with doxorubicin (lane 2), a histone deacetylase inhibitor (HDI, sodium butyrate, l
analyzed for clusterin (A), polyADP-ribose polymerase, PARP (B), or pro-caspase 3
was hyper-expressed following doxorubicin/HDI treatment panel A, lane 4, correspon
blots of untreated (lanes 1 and 3) or doxorubicin/HDI-treated samples (lanes 2 and 4)
its immunogenic peptide, which blocked the clusterin band. (E) Expression analysis
cells were untreated (lane 1), or treated with doxorubicin (lane 2), HDI (lane 3), or
indicated to the left of the figure. The results show an additive increase in doxorubicin
HDI alone. (F) Clusterin expression shown by RT-PCR in which actin primers were
demonstrating the absence of a 186-bp band representing the exon 1–3 splice variansodium butyrate for 48 h caused a marked increase in
p112PARP (the full-length form of poly ADP-ribose polymerase)
cleavage (Fig. 1A, lanes 3–5) and apoptotic cells (Fig. 1E)
compared to doxorubicin or sodium butyrate alone (Fig. 1A,
lanes 2 and 6–8, and Fig. 1C and D). Both results are
representative of more than three independent experiments.
Clusterin was moderately induced by doxorubicin and sodium
butyrate (Fig. 2A, lanes 2–3), as reported previously [11,17]
while combined doxorubicin-sodium butyrate treatment caused
a 2.4-fold hyper-expression of clusterin (Fig. 2A, lane 4)
compared to doxorubicin alone. At this time and dose, p112PARP
and pro-caspase 3 were efficiently cleaved (Fig. 2B and C, lane
4), indicating that the cells were apoptotic. The 60-kDa band
detected in Fig. 2Awas completely blocked by the immunogenic
peptide, demonstrating that the antibody was specific for
clusterin (Fig. 2D, lanes 3 and 4). Thus, chemotherapy/sodium
butyrate combinations synergize to induce apoptosis while
paradoxically inducing the anti-apoptotic protein clusterin.
Doxorubicin caused a 6-fold induction of clusterin RNA (Fig.
2E, lanes 1 and 2) that increased by 50% with the addition of
sodium butyrate (Fig. 2E, lane 4), an effect that is approximately
additive. In contrast, the effect of doxorubicin and sodium
butyrate on clusterin protein levels is more than additive,
suggesting that the hyper-expression of clusterin following
doxorubicin/HDI treatment is not due solely to increased
transcription. The primers used for this analysis detected exons. For panels A–C and E, MDA-MB-231 cells were untreated (lane 1), or treated
ane 3), or doxorubicin plus HDI (lane 4) for 48 h. (A–C) Western blots were
(C), with tubulin as a control for protein loading. The 60-kDa form of clusterin
ding with a synergistic increase in apoptosis panels B and C, lane 4. (D) Western
were probed with the clusterin antibody, without (left lanes) or with (right lanes)
of clusterin (upper band) or actin (lower band) by RT-PCR. As for panels A–C,
doxorubicin plus HDI (lane 4). The migration of molecular weight markers is
transcription following doxorubicin/HDI treatment compared to doxorubicin or
not included in the reaction. The reaction was amplified for additional cycles,
t. Actin was amplified as a loading control in a separate reaction (bottom panel).
Fig. 3. Multiple chemotherapeutic drugs and HDI's induce clusterin hyper-
expression. (A) Clusterin was induced by doxorubicin/HDI treatment in the p53-
negative breast cancer cell line MDA-MB-435S. Cells were untreated (lane 1) or
treated with 1 μM doxorubicin (lane 2), HDI (5 mM sodium butyrate, lane 3), or
doxorubicin/HDI (lane 4). (B) Following doxorubicin/HDI treatment, p112PARP
was efficiently cleaved (lane 4). MDA-MB-435S cells also demonstrated
increased sensitivity to doxorubicin (lane 2) compared to MDA-MB-231 cells.
(C) In MDA-MB-231 cells, clusterin was induced by doxorubicin (lane 2) and
50 μM SAHA (lane 3) and hyper-expressed following treatment with
doxorubicin plus SAHA (lane 4), indicating that multiple histone deacetylase
inhibitors increase clusterin levels. (D) Multiple HDI/chemotherapy combina-
tions increase clusterin levels. Clusterin was induced by the HDI sodium
butyrate (lane 2), 1 μM camptothecin (cp, lane 3), and 10 μM etoposide (etp,
lane 4), and was hyper-expressed following camptothecin/HDI (lane 5) and
etoposide/HDI (lane 6) treatment.
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1–3 splice variant, which has been reported previously in breast
cancer [32], would produce a 186-bp product. Actin was
included as an internal control for cDNA loading (Fig. 2E, lanes
1–4), and the shorter 186 bp clusterin fragment was not
detectable even when actin primers were not included in the
reaction (Fig. 2F, lanes 5 and 6).
The hyper-expression of clusterin following doxorubicin/
HDI treatment was also detected in the breast cancer cell line
MDA-MB-435S (Fig. 3A, lane 4). Notably, MDA-MB-435S
cells were more sensitive to doxorubicin-induced apoptosis than
MDA-MB-231 cells when used as a single agent (compare Fig.
3B, lane 2, and Fig. 2B, lane 2). Clusterin hyper-expression was
induced bymultiple HDIs including SAHA (Fig. 3C, lane 4) and
trichostatin A (data not shown). Furthermore, the topoisomerase
I and II inhibitors camptothecin and etoposide induced clusterin
(Fig. 3D, lanes 3 and 4), as reported previously [17], and led to
clusterin hyper-expression when used in combination with
sodium butyrate (Fig. 3D, lanes 5–6). We conclude that multiple
chemotherapy/HDI combinations lead to hyper-expression of
clusterin.
3.2. Clusterin localizes to mitochondria and suppresses
cytochrome c release
Clusterin co-purified with a heavy membrane fraction
containing mitochondria (Fig. 4A, lanes 2–4) after doxorubicin,
sodium butyrate, or doxorubicin/sodium butyrate treatment,
similar to a recent report which used an exogenous expression
system in fibrosarcoma and prostate cancer cells [34]. Clusterin
co-fractionated with the mitochondrial marker COXII (Fig. 4B),
but not the cytoplasmic marker Akt (Fig. 4C), and tubulin was
used as a control for protein loading throughout (Fig. 4D). This
result was confirmed by immunofluorescence, which revealed
that a fraction of clusterin co-localized with mitochondria (Fig.
4E–G), and there was additional clusterin staining that radiated
into the cytoplasm (Fig. 4E).
To test the identity of proteases that might regulate clusterin
levels, MDA-MB-231 cells were treated with the proteasome
inhibitors epoxomicin [43,44] or MG132. Clusterin levels
increased significantly following treatment with 100 nM epox-
omicin (Fig. 4H, lane 3) or 10 μMMG132 (Fig. 4H, lane 4), both
in MDA-MB-231 (Fig. 4H, lanes 1–4) and MDA-MB-435S cells
(Fig. 4H, lanes 5–7). We conclude that clusterin stability is
increased by proteasome inhibition in breast cancer cells.
Next, we inhibited clusterin by RNAi and followed with HDI
alone or with increasing doses of doxorubicin (Fig. 5A,
compare lanes 2–5 with lanes 7–10). Following HDI treatment,
clusterin inhibition increased the cleavage of p112PARP (Fig.
5B, lanes 2 and 7), so that the ratio of the p85/p112 forms
increased 37-fold when clusterin was absent, suggesting that
clusterin suppressed sodium butyrate-induced apoptosis. We
detected a similar effect on caspase 3 cleavage, an additional
marker of apoptosis (data not shown). In clusterin-inhibited
cells, the level of PARP cleavage did not increase further with
the addition of 0.04–0.2 μM doxorubicin (Fig. 5B, compare
lane 7 with lanes 8–9). At the highest dose of doxorubicin, therewas no difference in apoptosis between control and clusterin-
inhibited cells (Fig. 5B, lanes 5 and 10).
Clusterin suppressed the release of cytochrome c into the
cytoplasm following HDI treatment (Fig. 5C, compare lanes 2
and 5). In spite of the elevated levels of apoptosis in
doxorubicin-sodium butyrate-treated cells (Fig. 2A and E, 3B,
and 5B), cytochrome c release was similar to that of sodium
butyrate-treated cells (Fig. 5C, lanes 2–3), even in the absence of
clusterin (Fig. 5C, lanes 5–6). This suggested that apoptosis
induction was not dependent on mitochondrial membrane
permeability. For these experiments, the mitochondrial and
cytoplasmic markers were the same as described above. We
conclude that clusterin localized to mitochondria and suppressed
Fig. 5. Clusterin inhibits apoptosis and cytochrome c release after histone
deacetylase inhibitor treatment. MDA-MB-231 breast cancer cells were
transfected with oligonucleotide RNAi duplexes targeting a control sequence
(lanes 1–5) or clusterin (lanes 6–10). Cells were left untreated (lanes 1 and 6) or
were treated with 5 mM sodium butyrate (lanes 2 and 7), or sodium butyrate in
combination with 0.04 μM doxorubicin (lanes 3 and 8), 0.2 μM doxorubicin
(lanes 4 and 9), or 1 μM doxorubicin (lanes 5 and 10). (A) Clusterin protein
levels increased moderately with HDI (lane 2) and increased further with 0.04–
1 μM doxorubicin (lanes 3–5), while clusterin expression was effectively
inhibited by RNAi (lanes 6–10). (B) Treatment with HDI alone did not induce
apoptosis in control cells (lane 2) but did where clusterin was inhibited (lane 7).
Although high levels of doxorubicin increased apoptosis in combination with
HDI (lane 5), there was no further increase in PARP cleavage with the addition
of 0.04–1 μM doxorubicin–HDI treatment where clusterin was inhibited (lanes
8–10). Lower panel: tubulin is included as a control for protein loading. (C–E)
Clusterin inhibits cytochrome c release after HDI treatment. Control (lanes 1–3
and 7–9) or clusterin-inhibited (lanes 4–6 and 10–12) cells were fractionated
into cytoplasmic (lanes 1–6) or mitochondrial/heavy membrane (lanes 7–12)
fractions and probed for cytochrome c (C), COX II (D), or Akt (E). Cytochrome
c release was increased in clusterin-inhibited cells (lanes 5–6) compared to
control cells (lanes 2–3). Cytochrome c oxidase (COX II) was a mitochondrial
marker, while Akt served as a cytoplasmic marker. We conclude that clusterin
suppresses cytochrome c release and apoptosis following treatment with histone
deacetylase inhibitors, but that chemotherapy–HDI-induced caspase activation
is clusterin-resistant.
Fig. 4. A clusterin fraction localizes to mitochondria. MDA-MB-231 cells that
were untreated (lanes 1 and 5) or treated with doxorubicin (lanes 2 and 6), HDI
(lanes 3 and 7), or doxorubicin/HDI (lanes 4 and 8) were separated into
mitochondrial/heavy membrane (mito/HM, lanes 1–4) and cytoplasmic (lanes
5–8) fractions and analyzed by western blot for clusterin (A), the mitochondrial
marker COX II/cytochrome c oxidase IV, sub-unit II (B), the cytoplasmic
marker Akt (C), or tubulin (D), as a control for total protein loading. (E)
Immunofluorescence for clusterin showing a perinuclear and punctuate
cytoplasmic staining pattern. (F) Immunofluorescence for COXII showing its
mitochondrial localization. (G) A merged view of panels E and F, showing
overlapping staining in yellow. (H) Clusterin is inhibited by the proteasome.
MDA-MB-231 (lanes 1–4) or MDA-MB-435S (lanes 5–7) cells were untreated
(lanes 1 and 5) or treated with 1 μM doxorubicin (lanes 2 and 6), 100 nM
epoxomicin (lanes 3 and 7), or 10 μMMG-132 (lane 4). Protein expression was
analyzed by western blot, with tubulin as a control for loading.
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clusterin-resistant apoptotic mechanism was activated by
chemotherapy–HDI treatment.
3.3. The extrinsic apoptotic pathway is activated by
doxorubicin–HDI treatment
Our results suggested that apoptotic pathways other than the
intrinsic/mitochondrial pathway may be stimulated by doxor-
ubicin/HDI treatment. While clusterin levels increased afterdoxorubicin–sodium butyrate treatment (Fig. 6A, lane 4), pro-
caspase 8 was almost completely cleaved (Fig. 6B, lane 4). Pro-
caspase 8 proteolysis led to a corresponding increase in its
enzymatic activity (Fig. 6G, compare columns 2–3 with column
4). Following clusterin inhibition by RNAi, there was little
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doxorubicin, sodium butyrate, or doxorubicin/sodium butyrate
treatment (Fig. 6H, middle panel, compare lanes 1–4 with lanes
5–8). In addition to pro-caspase 8, IκBα was largely undetect-
able following doxorubicin/sodium butyrate treatment (Fig. 6C,
lane 4), while Fas ligand and the Fas binding complex protein
FADD (Fas-associated death domain [45,46]) were increased
(Fig. 6D and E). In contrast, RIP (receptor interacting protein)
increased with doxorubicin and decreased with doxorubicin/
HDI treatment (Fig. 6F, lanes 2 and 4). We conclude that
multiple steps in the extrinsic apoptosis pathway are altered by
chemotherapy/HDI combined treatment, but that clusterin does
not regulate pro-caspase 8 activation.
4. Discussion
Following DNA damage, we have found that clusterin
suppresses the intrinsic apoptosis pathway by limiting
cytochrome c release (Fig. 7, left), while our data support a
model in which histone deacetylases reduce the activity of the
extrinsic apoptosis pathway. As a result, apoptosis is largelyFig. 6. Chemotherapy–HDI combinations increase pro-caspase 8 activation. (A) MD
2), 5 mM HDI (sodium butyrate, lane 3), or doxorubicin plus HDI (lane 4) for 48 h.
FasL, (E) FADD, (F) RIP and tubulin as indicated. Fold changes in protein expressi
Cells were treated as for part A, and caspase 8 activity was measured in the lysa
p-nitroanilide). The analysis was repeated in triplicate, and fold change in activity re
oligonucleotide RNAi duplexes targeting a control sequence (lanes 1–4) or clusterin
doxorubicin (lanes 2 and 6), HDI (5 mM sodium butyrate, lanes 3 and 7), doxorubicin
caspase 8 and tubulin as indicated. The results show that caspase 8 is activated foll
cleavage.suppressed, which limits the effectiveness of chemotherapy.
In contrast, combining DNA damage with inhibitors of
histone deacetylases triggers the extrinsic apoptosis pathway,
circumventing the ability of clusterin to suppress apoptosis
(Fig. 7, right). The ability of HDIs to suppress the extrinsic
apoptosis pathway has been reported previously in leukemia
[47], and this report links histone deacetylase-mediated
repression of the extrinsic apoptosis pathway to damage-
induced apoptosis.
It is somewhat paradoxical that histone deacetylase inhibi-
tors induce components of the extrinsic apoptosis pathway
while increasing clusterin levels (which inhibits the intrinsic
apoptosis pathway). The majority of breast cancers express low
levels of clusterin basally [18], and clusterin transcription is
induced markedly following treatment with multiple types of
chemotherapy [17,18]. The common regulatory point between
clusterin and the extrinsic pathway may be the proteasome [48].
Our results suggest that the proteasome inhibits clusterin levels
in multiple cell lines (Fig. 4). However, a second proteasome
target, IκBα [49], is degraded in doxorubicin/HDI-treated cells
under the same conditions that stabilize clusterin. TheseA-MB-231 cells were untreated (lane 1), or treated with 1 μM doxorubicin (lane
Western blots were analyzed for (A) clusterin, (B) pro-caspase 8, (C) IκBα, (D)
on/tubulin ratios, relative to untreated cells, are indicated below each panel. (G)
tes using the chromogenic substrate Ac-IETD-pNA (N-acetyl-Ile-Glu-Thr-Asp
lative to untreated cells is shown. (H) MDA-MB-231 cells were transfected with
(lanes 5–8). Cells were left untreated (lanes 1 and 5) or were treated with 1 μM
–HDI combined (lanes 4 and 8). Western blots were analyzed for clusterin, pro-
owing doxorubicin–HDI treatment, and that clusterin does not affect caspase 8
Fig. 7. Diagram depicting the relationship between clusterin, the intrinsic and extrinsic apoptotic cascades, and histone deacetylases. We have shown that clusterin co-
localizes with mitochondria and suppresses cytochrome c release, which triggers apoptosis. Clusterin is regulated by the proteasome, although it is unclear if this
regulation is direct. The clusterin-mediated inhibition of the intrinsic apoptotic pathway can be bypassed by activation of the extrinsic pathway, although the precise
mechanism through which histone deacetylases perform this function is not known.
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were inhibited by a second proteolytic pathway, and one
candidate is calpain, which inhibits clusterin levels (data not
shown). This multi-step regulation of clusterin may be due to
cancer cells degrading clusterin to limit the anti-proliferative
effect that it has on some cell lines [50].
There are several notable points involving the induction of
apoptosis by chemotherapy/HDI combinations. As a single
agent, sodium butyrate treatment triggered modest levels of
cytochrome c release and increased levels of IκBα (Fig. 6C),
as reported previously for other cell types [14,51]. The
addition of a DNA damaging agent induced elevated levels of
apoptosis (Figs. 1–3, 5 and 6), pro-caspase 8 activation, and
induction of components of the extrinsic apoptosis pathway
[52], without an increase in cytochrome c release (Fig. 5C).
Previous work has shown that butyrate induces the transcrip-
tion of caspase 8 [53], although we did not detect this change
in breast cancer cells (data not shown). Butyrate has also been
linked to increased expression of death receptors and other
apoptosis-related genes in cancer [54–56], and we detected
elevated levels of IκBα, Fas ligand, FADD, RIP, and TRAIL
in butyrate-treated breast cancer cells (data not shown).
However, IκBα and RIP decreased substantially when
doxorubicin and HDI were combined, consistent with an
anti-apoptotic role for RIP in some cell types [57,58]. Thus,
our results are consistent with a model in which chemother-
apy–HDI combinations trigger the extrinsic apoptotic pathway
through multiple expression changes in the components of this
pathway.
Histone deacetylase inhibitors have been tested in clinical
trials for cancer, where they have achieved modest success
as single agents. Our results suggest that clusterin reduces
the tumoricidal activity of these drugs by inhibiting
apoptosis. HDIs induce clusterin transcription [11,53,59],and our results suggest that clusterin induction inhibits the
effectiveness of the drugs. We chose butyrate for several
experiments because it is a natural product of the digestive
tract (and is a major component of butter) that was used at
concentrations that are lower than physiological levels
(which can exceed 100 mM). The effects of butyrate on
proliferation and apoptosis are diverse, and include profound
effects on differentiation [3,4,12,60], even in breast cancer
cells [61]. In MDA-MB-231 cells, sodium butyrate triggered
arrest in G2/M, increased sub-G1 content, and G1 arrest (Fig.
1). Clusterin can be inhibited clinically by the antisense
oligonucleotide OGX-011, which is currently in clinical
trials for prostate and lung cancer, and which sensitizes
breast cancer cells to several types of chemotherapeutic
agents [18,62]. Our results suggest that OGX-011 combined
with histone deacetylase inhibitors may be useful for treating
some types of cancer. Furthermore, post-treatment clusterin
levels may be a useful biomarker for clinical trials utilizing
HDIs because tumors with high post-treatment levels of
clusterin may be more resistant to HDIs clinically than
tumors expressing low clusterin levels.
Although this study focuses on cancer chemosensitivity,
clusterin expression has been linked to numerous diseases and
physiological states, including Alzheimer's, ischemia, and
aging. It is likely that histone deacetylases play an important
role in regulating clusterin stability in multiple tissues exposed
to various types of stress. Indeed, histone deacetylase
inhibitors may be useful in the treatment of inflammatory
diseases [63], and clusterin may contribute to the effectiveness
of these approaches. Inhibitors of histone deacetylases are
undergoing clinical trials for cancer and other diseases, and our
results suggest that clusterin may be useful both as a
biomarker for the action of these drugs, as well as a target
to improve their effectiveness.
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